Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • Trev
    Junior Member
    • Dec 2011
    • 1

    #1

    PacBio performance and efficiency in the field

    I have been searching for some down to earth information regarding how the PacBio RS is actually performing that doesn't come from PacBio marketing in terms of both the wet bench side as well as the data quality coming off the system. Is there a honest review of the system out there yet? The system has been out there for awhile now.

    For instance, how is the system performing? I was at a seminar where a sales rep publicly indicated they were having variability problems.

    How many SMRT cells are actually required to not only produce whole-genome sequence data for say an E. coli BUT to produce enough and good enough sequence that can be assembled? The reason I ask is that it looks like from the PacBio publication on the O104 outbreak that it took >50 SMRT cells (cells for both closed circular and long subreads) to assemble the single outbreak isolate. Does it really take this many to get an assembly with PacBio data? Why collect so many if it doesn't?

    What is the final cost of getting assembly quality whole-genome sequencing data off of the PacBio given the number of SMRT cells that need to be run?

    Is the best use of the PacBio RS for whole-genome sequencing in combination with other sequencing data of higher quality and throughput like an Illumina system?

    Is anyone using the PacBio RS for whole-genome sequencing of genomes larger than microbes?

    Is there any public review on the web that lists this information that anyone can link to or comment on? It seems like it is slim pickings out there for actual information.
  • wweise
    Junior Member
    • Jul 2011
    • 1

    #2
    PacBio information from customers

    Full disclosure, I am from the marketing department at Pacific Biosciences but didn't want your question to go unanswered. We have just launched several application-focused pages on our website with customer results, including: webinars, technical posters, peer-reviewed publications, etc. Please visit: www.pacb.com/apps. I hope this helps answer some of your questions....

    Comment

    • petang
      Member
      • Nov 2008
      • 13

      #3
      I am using PB to do de novo genome sequencing of an ~170MB genome.
      The followings are the results form 4 SMRT cells:
      % Adapter Dimer (0-10bp) 3.96
      % Short Insert (11-100bp) 0.51
      Pre-Filter # of Bases 985171659
      Post-Filter # of Bases 537023600
      Pre-Filter # of Reads 601168
      Post-Filter # of Reads 132250
      Pre-Filter Mean Readlength 819
      Post-Filter Mean Readlength 3393
      Pre-Filter Mean Read Quality 0.191
      Post-Filter Mean Read Quality 0.842

      Therefore, around 22% of the reads are QUALITY reads.
      The mean read length of 3Kb is good enough though.

      I will to assemble the datasets and update the result later.

      Comment

      Latest Articles

      Collapse

      • SEQadmin2
        Beyond CRISPR/Cas9: Understand, Choose, and Use the Right Genome Editing Tool
        by SEQadmin2



        CRISPR/Cas9 sparked the gene editing revolution for both research and therapeutics.1 But this system still showed severe issues that limited its applications. The most prominent were the heavy reliance on PAM sequences, delivery limitations, double-stranded breaks that prompt unintended edits and cell death, and editing inefficiency (both in targeting and in knock-in reliability).

        Despite this, “CRISPR helped turn genome editing from a specialized technique into
        ...
        Yesterday, 11:01 AM
      • SEQadmin2
        Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
        by SEQadmin2


        Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

        The systematic characterization of the human proteome has
        ...
        07-20-2026, 11:48 AM
      • SEQadmin2
        Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
        by SEQadmin2



        Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
        ...
        07-09-2026, 11:10 AM

      ad_right_rmr

      Collapse

      News

      Collapse

      Topics Statistics Last Post
      Started by SEQadmin2, Yesterday, 02:55 AM
      0 responses
      12 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 07-24-2026, 12:17 PM
      0 responses
      12 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 07-23-2026, 11:41 AM
      0 responses
      13 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 07-20-2026, 11:10 AM
      0 responses
      24 views
      0 reactions
      Last Post SEQadmin2  
      Working...